Sponsors (3)
The bill promotes faster, more transparent multi‑stakeholder input into rare‑disease product development and clearer regulatory processes, but it increases administrative burdens, raises conflict‑of‑interest and confidentiality risks, and relies on modest funding that may limit its effectiveness.
Patients with rare diseases: clinical development may move faster and be clearer because multi‑stakeholder consensus on trial designs, endpoints, and biomarkers will guide development decisions.
Patients, researchers, and the public: meeting transcripts, recordings, and published summaries (including documented consensus and next steps) will be available within 180 days, increasing transparency and access to deliberations.
Developers, researchers, and small businesses: a standing steering committee with FDA, academics, patients, and industry will provide regulatory clarity by setting topics and processes for engagement and guidance.
Patients and small developers: industry representation on the steering committee and in meetings could create perceived or actual conflicts of interest, biasing processes toward industry‑friendly pathways.
FDA review divisions, hospitals, and researchers: participating in meetings and producing follow‑up reports/transcripts will increase administrative workload and strain agency resources.
Small businesses and researchers: public summaries may need to omit confidential commercial or trade‑secret details, reducing usefulness for sponsors and possibly delaying disclosure of technical information.
Based on analysis of 2 sections of legislative text.
Requires HHS/FDA to establish externally led, science‑focused rare‑disease drug development meetings run by the Reagan‑Udall Foundation and create a permanent steering committee to guide them.
Introduced February 24, 2025 by Doris Matsui · Last progress February 24, 2025
Creates a formal process for externally led, science-focused drug development (EL–SFDD) meetings to bring together FDA staff, medical experts, drug developers, scientific groups, and patient organizations to address scientific challenges in developing drugs for rare diseases. Directs HHS/FDA to arrange with the Reagan-Udall Foundation to convene at least four disease-focused EL–SFDD meetings per year and requires the Foundation to set up a permanent multistakeholder steering committee to guide meeting topics and implementation.